
Please try another search
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Richard D. Klausner | 73 | 2018 | Founder & Executive Chairman |
Otis Webb Brawley | 65 | 2021 | Independent Director |
Lynn Seely | 66 | 2021 | President, CEO & Director |
Catherine J. Friedman | 65 | 2018 | Lead Independent Director |
William J. Rieflin | 65 | 2020 | Independent Director |
Elizabeth G. Nabel | 73 | 2021 | Independent Director |
Sumant Ramachandra | 56 | 2024 | Independent Director |
Mark J. Bachleda | 50 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review